A sharp intake of breath. Amelia pressed herself further into the shadows, the rich scent of leather and old books filling her nostrils. His gaze. It burned into the space where the 'Phase II Progress Report' lay, slightly askew. A muscle twitched in Rhys's jaw. He reached out, his long fingers brushing the edge of the folder. He didn't pick it up. Instead, he simply straightened it with a precise, almost unconscious movement. Then, he turned away, striding to his immense mahogany desk. Amelia released a silent exhale she hadn't realized she was holding. He hadn't seen her. Not yet. Minutes stretched into an eternity. His back was to her, focused on his own work, the soft glow of a desk lamp illuminating his sharp profile. Slowly, carefully, Amelia began her retreat. One foot, then the other. The plush carpet swallowed the sound of her escape. She slipped out, the heavy door latch clicking softly behind her, a sound barely audible above the frantic drumbeat against her ribs. Back in her own sterile office, the incident replayed. 'Project Chimera'. The phrase echoed in her mind. It was the key, she knew it. But Rhys’s assignment—optimize resource allocation, streamline research, accelerate Phase III trials—felt like a direct path to cutting corners, to sacrificing integrity for speed. Her own integrity screamed in protest. Her promise to her mother, to herself, weighed heavily. She wouldn't be like *them*. She wouldn't compromise. Days bled into a week. Amelia scoured data, ran simulations, stared at spreadsheets until her eyes ached. Every proposed solution felt tainted. Push for faster results, risk patient safety. Cut costs, compromise data quality. It was a tightrope walk over a chasm of ethical compromise. She rejected every draft, every strategy. The pressure mounted. Rhys's expectations were a tangible weight, pressing down on her shoulders. Failure wasn't an option, not if she wanted to uncover the truth about her mother. One restless night, the answer clicked. Not a compromise, but a re-framing. The problem wasn't just about speed or cost. It was about *efficiency*. True efficiency, she realized, wasn't about doing more with less. It was about doing the *right* things with the resources available, eliminating waste, and focusing on true innovation. What if they re-evaluated the *entire* trial design? Not just the budget or timeline. What if certain redundant tests could be consolidated? What if patient recruitment protocols could be refined to target specific demographics more effectively, reducing screening failures and maximizing impact? It wasn't about forcing faster results. It was about *smarter* results. Amelia worked obsessively. Diagrams, flowcharts, revised budget models. Her proposal focused on refining the *methodology* of Phase III. It suggested a staggered, adaptive trial design, allowing for real-time data analysis to inform subsequent stages, rather than waiting for full completion. This approach, she argued, would reduce the overall duration and cost, not by cutting corners, but by optimizing the learning process itself. It meant less waste, better data, and ultimately, faster *ethical* approvals through a more robust and responsive framework. A week later, Amelia walked into Rhys’s office. Her proposal was a thick binder, meticulously organized, its tabs clearly labeled. She laid it on his immense mahogany desk. He looked up, his expression unreadable, his gaze cold as ice.

Chapter 19: The Elegant Solution